BioNTech (NASDAQ:BNTX) Given “Buy” Rating at Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research note published on Thursday morning,Benzinga reports. Canaccord Genuity Group currently has a $171.00 target price on the stock.

BNTX has been the topic of several other reports. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and boosted their price objective for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. Bank of America raised their price target on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. JPMorgan Chase & Co. lowered their price objective on BioNTech from $125.00 to $124.00 and set a “neutral” rating on the stock in a research report on Monday, November 4th. HC Wainwright increased their price target on BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Finally, TD Cowen dropped their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and a consensus target price of $137.54.

BioNTech Trading Down 3.7 %

BNTX stock opened at $99.72 on Thursday. The business has a fifty day moving average of $113.54 and a 200-day moving average of $97.29. The company has a market cap of $23.91 billion, a P/E ratio of -47.49 and a beta of 0.26. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s revenue was up 38.9% on a year-over-year basis. During the same period last year, the company earned $0.73 EPS. As a group, equities research analysts expect that BioNTech will post -3.68 EPS for the current year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds have recently made changes to their positions in BNTX. Vestcor Inc acquired a new position in BioNTech in the third quarter valued at $784,000. Y Intercept Hong Kong Ltd bought a new position in shares of BioNTech during the 3rd quarter worth approximately $718,000. XTX Topco Ltd acquired a new stake in shares of BioNTech during the 3rd quarter worth approximately $459,000. State Street Corp grew its holdings in BioNTech by 2.0% in the third quarter. State Street Corp now owns 155,867 shares of the company’s stock worth $18,512,000 after purchasing an additional 3,014 shares during the period. Finally, Redmile Group LLC bought a new stake in BioNTech in the 3rd quarter valued at about $18,345,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.